- Evaluate safety and efficacy of FDA-approved topical therapies for managing AD in children
- Develop a personalized AD treatment plan incorporating novel topical therapies based on child-specific needs & clinical characteristics
DermNexus: The Inflammatory Disease and Innovations Congress for NP/PAs: Spotlight CE Sessions
Scroll down to view information on each symposium. These symposia are hybrid. In-Person registration is included as part of DermNexus registration.
Pediatric Atopic Dermatitis: Role of Advanced Topical Therapies in Optimizing Management
November 20, 2026 11:50 AM - 12:20 PM MT
OVERVIEW
Atopic dermatitis typically has an onset before the age of 5 years, and persistent AD beyond infancy may affect approximately 50% of patients diagnosed with AD during childhood. The condition can have substantial effects on the quality of life of both patients and their families. In this program, expert faculty will provide insights and updates on the use of topical therapies in children with AD to help learners provide personalized treatment.
LEARNING OBJECTIVES
TARGET AUDIENCE
This program is directed toward dermatology NPs, PAs, and other healthcare professionals involved in the diagnosis and management of patients with AD.
ACCREDITATION/CREDIT DESIGNATION
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACKNOWLEDGEMENT OF EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.
259 Prospect Plains Rd, Building H, Monroe, NJ 08831
Copyright ©2026
Physicians' Education Resource®, LLC.
All rights reserved
.png)